OCS‑01 enters phase 3 DIAMOND

Diabetic macular edema is a retina disease, but the real story here is treatment burden. Today, most patients who need active therapy end up on repeat injections into the eye, often with frequent follow-up visits. That works, but it is invasive, clinic-heavy, and not ideal for people with earlier disease or patchy response. The news is that Oculis has now completed the final patient visits in its phase 3 DIAMOND program for OCS-01, a topical dexamethasone eye drop, with topline results expected in June 2026. ### What is OCS-01, exactly? OCS-01 is a high-concentration dexamethasone ophthalmic suspension designed as an eye drop, not an injection. The whole pitch is that Oculis is trying to get a steroid formulation to reach the back of the eye well enough to matter in diabetic macular edema, which is the swelling of the macula caused by diabetic retinal disease. Oculis describes the drug as a 15 mg/mL dexamethasone formulation built on its OPTIREACH delivery platform. (biospace.com) ### Why is DME such a hard target for drops? Because the retina sits in the back of the eye, and ordinary drops usually do a poor job reaching that tissue at meaningful levels. That is why standard DME care has centered on intravitreal anti-VEGF injections and, in some cases, steroid implants or injections. A drop that actually works would be unusual here — basically the whole reason this program stands out. (oculis.com) ### What is the DIAMOND program testing? DIAMOND is not one small study. It is a pair of phase 3, double-masked, randomized, vehicle-controlled, multicenter trials — DIAMOND-1 and DIAMOND-2 — built as pivotal studies for registration. Oculis said the two trials enrolled more than 800 patients across 119 sites, mostly in the US, and each study followed patients for 52 weeks. ClinicalTrials.gov lists DIAMOND-2 with actual enrollment of 401 and completion in April 2026. (biospace.com) ### Didn’t OCS-01 already have phase 3 data? Yes — but from an earlier stage. In October 2023, Oculis reported that stage 1 of the phase 3 DIAMOND trial met its primary and secondary endpoints and helped lock in the dose regimen for the larger global studies. In that stage, best-corrected visual acuity improved by 7.2 letters at week 6 with OCS-01 versus 3.1 letters with vehicle, and the retinal-thickness result also favored the drop. (biospace.com) ### So what changed now? The key milestone is operational, not clinical. Oculis has finished the last patient visit across both confirmatory phase 3 trials, which means the dataset is now effectively closed for topline analysis. That matters because it moves the story from “promising program” to “near-term readout,” with the company pointing to June 2026 for results and saying an NDA could follow if the data are positive. (investors.oculis.com) ### Who would use this if it works? Probably not as a total replacement for injections on day one. The more realistic first use case is patients who are untreated because the burden of injections feels too high, plus patients who have an incomplete response to anti-VEGF therapy. That is where a non-invasive option could change behavior — not because drops are magically better, but because doctors and patients may accept treatment earlier and more often when the friction is lower. (biospace.com) That is an inference from the trial framing and company messaging, not confirmed market uptake yet. ### What is the catch? A drop still has to prove it can deliver durable, clinically meaningful benefit over a full year, not just look interesting in a shorter study. Steroids also come with familiar eye-safety questions, especially around intraocular pressure and cataract risk, so the phase 3 readout has to show a benefit-risk profile strong enough to justify use in a chronic retinal disease. The absence of posted phase 3 results so far means the big question is still unanswered. (biospace.com) ### Bottom line This is one of those biotech stories where the form factor is the point. If OCS-01 hits in June, DME treatment could start to look less like a procedure business and more like a drug business. But until the phase 3 numbers land, “eye-drop alternative to injections” is still a live hypothesis, not a solved problem. (biospace.com) (clinicaltrials.gov)